GLUE NASDAQ
Monte Rosa Therapeutics, Inc.
1W: -6.2%
1M: -9.0%
3M: -50.6%
YTD: -30.4%
1Y: -4.3%
3Y: +289.1%
5Y: -52.8%
$10.66
+0.18 (+1.72%)
Weekly Expected Move ±9.1%
$9
$10
$11
$12
$13
Credit Risk of going bust: higher than 56% of companies Debt: 4.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.08 (down 99.3%), Monte Rosa Therapeutics, Inc. would be worth roughly what it owes.
Total debt $38.0M against a stock market value of $909.4M.
Distance to default 4.57 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $21.3M (short-term plus half of long-term), stock volatility 78.8%; Altman Z'' 3.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.08 (down 99.3%), Monte Rosa Therapeutics, Inc. would be worth roughly what it owes.
Total debt $38.0M against a stock market value of $909.4M.
Distance to default 4.57 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $21.3M (short-term plus half of long-term), stock volatility 78.8%; Altman Z'' 3.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (96)
Are Options Traders Betting on a Big Move in Monte Rosa Therapeutics Stock?
Monte Rosa Therapeutics Sees Unusually Large Options Volume (NASDAQ:GLUE)
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Has Consensus Target Price of $26.67 According to Analysts
Brokers Set Expectations for GLUE Q3 Earnings
Monte Rosa plans mid-stage trials for anti-inflammatory agent after positive Phase 1 data
At a glance: stocks gapping up premarket
Monte Rosa Therapeutics, Inc. $GLUE Shares Newly Acquired by Bank of America Corp DE
Analysts Set Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Target Price at $28.50
Legal & General Group Plc Acquires New Stake in Monte Rosa Therapeutics, Inc. $GLUE
Bank of America Corp DE Raises Stock Position in Monte Rosa Therapeutics, Inc. $GLUE
Dimensional Fund Advisors LP Acquires 473,005 Shares of Monte Rosa Therapeutics, Inc. $GLUE
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Gap Down – Here’s What Happened
Arrowstreet Capital Limited Partnership Acquires 340,088 Shares of Monte Rosa Therapeutics, Inc. $GLUE - marketbeat.com
Swiss National Bank Invests $1 Million in Monte Rosa Therapeutics, Inc. $GLUE - marketbeat.com
Why Monte Rosa Therapeutics (GLUE) Is Down 27.5% After Novo Nordisk’s ZEUS Trial Missed Its Goal - simplywall.st
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection? - Stocktwits
Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial
Monte Rosa, BioAge plunge after Novo’s setback (GLUE:NASDAQ) - Seeking Alpha
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Gap Down - Should You Sell? - marketbeat.com
$GLUE stock is down 31% today. Here's what we see in our data. - Quiver Quantitative
Novo Nordisk drops as anti-inflammatory drug fails in late-stage trial
Why is Monte Rosa Therapeutics stock plunging today? - Investing.com
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Consensus Recommendation of "Moderate Buy" by Analysts - marketbeat.com
Monte Rosa Therapeutics (GLUE) to Release Earnings on Thursday - marketbeat.com
Exome Asset Management LLC Takes $2.95 Million Position in Monte Rosa Therapeutics, Inc. $GLUE - marketbeat.com
Allspring Global Investments Holdings LLC Buys 365,272 Shares of Monte Rosa Therapeutics, Inc. $GLUE - marketbeat.com
GLUE Oct 2026 2.500 call (GLUE261016C00002500) stock price, news, quote and history - Yahoo Finance UK
New super strong glue grips non-stick surfaces and wipes away easily - Phys.org
GLUE (NASDAQ: GLUE) holder to sell 9,500 shares under Rule 144 - Stock Titan
GLUE (NASDAQ: GLUE) holder plans 4,351-share sale after option exercise - Stock Titan
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Down 8.7% - Here's What Happened - MarketBeat
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?
After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?
10 small-cap U.S. healthcare stocks with the strongest momentum grades
Kymera, Monte Rosa among gainers as Novartis inks deal for molecular glue drugs
Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy
Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy - Yahoo Finance
GLUE - Monte Rosa Therapeutics Inc Stock Price and Quote - Finviz
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Trial Progress And Valuation Gap Draw Investor Attention
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics reports Q1 results
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics Inc (GLUE) Stock Price & News - Google
Brokerages Set Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) PT at $32.80
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells $103,398.05 in Stock
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives $32.80 Average PT from Analysts
Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer Story
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday Ahead of US Federal Reserve Meeting
Monte Rosa Therapeutics touts molecular glue pipeline, tees up GFORCE updates and Phase II plans
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics: Q4 Earnings Snapshot
Monte Rosa Therapeutics reports Q4 results
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Agenus (AGEN) Q4 Earnings and Revenues Surpass Estimates
Agenus (AGEN) Q4 Earnings and Revenues Surpass Estimates
Monte Rosa rises on J&J collaboration for cancer therapy trial
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives $31.33 Consensus PT from Brokerages
GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount - Stocktwits
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Significant Increase in Short Interest
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of “Moderate Buy” by Brokerages
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug
Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug - Yahoo Finance
Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Monte Rosa Therapeutics (GLUE) Upgraded to Strong Buy: Here's Why
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
Analyzing Monte Rosa Therapeutics (NASDAQ:GLUE) and NextCure (NASDAQ:NXTC)
Monte Rosa Scores A Win In Prostate Cancer, And Rockets To A Four-Year High
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
Monte Rosa: Looking Mispriced After Big Pharma Validation
BETTY NAMED CREATIVE AGENCY OF RECORD FOR GORILLA GLUE
GLUE Stock Price and Chart — NASDAQ:GLUE - TradingView